CXCR5 CAR-T cells

N/A

Report date: 2025/01/26 18:15:30

Base Information

Drug NameCXCR5 CAR-T cells
Drug Alias Nameanti-CXCR5 CAR T-cell therapy (Max Delbruck Centrum Fur Molekulare Medizin/Charite Universitaetsmedizin Berlin)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionC-X-C motif chemokine receptor 5 modulators
TargetsC-X-C motif chemokine receptor 5
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMax Delbruck Centrum Fur Molekulare Medizin
China Registration ClassN/A

Develop Information

Active CompaniesMax Delbruck Centrum Fur Molekulare MedizinCharité – Universitätsmedizin Berlin
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Non-Hodgkin +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A